Cell Therapeutics to Host Analyst and Investor Meeting on Advances and Existing Challenges in the Treatment of Myelofibrosis

    Cell Therapeutics to Host Analyst and Investor Meeting on Advances and
   Existing Challenges in the Treatment of Myelofibrosis with Live Webcast

PR Newswire

SEATTLE, Jan. 16, 2013

SEATTLE, Jan. 16, 2013 /PRNewswire/ --Cell Therapeutics, Inc. (CTI) (Nasdaq
and MTA: CTIC) announced today that CTI will provide a live audio and slide
webcast of its analyst and investor meeting to be held on January 23 in New
York. Expert speakers will focus on advances in treatment using JAK
inhibitors and existing challenges in treating myelofibrosis patients. Guest
speakers include:

Ross L. Levine, M.D., Associate Member at Memorial Sloan-Kettering Cancer
Center in the Human Oncology and Pathogenesis Program and Leukemia Service,
Associate Professor of Medicine at Weill Cornell Medical College

Srdan Verstovsek, M.D., Ph.D., Professor, Leukemia Department, Division of
Cancer Medicine, Chief, Section for Myeloproliferative Neoplasms, Leukemia
Department, and Director, Clinical Research Center for MPNs, at The University
of Texas MD Anderson Cancer Center

CTI recently initiated a Phase 3 clinical trial, known as PERSIST-1, for
pacritinib, CTI's investigational JAK2 inhibitor that is being evaluated for
the treatment of patients with myelofibrosis. 

Webcast Details

Date: Wednesday, January 23, 2013

Time: 9:00 a.m. Eastern/6:00 a.m. Pacific/3:00 p.m. Central European time to
10:30 a.m. Eastern/7:30 a.m. Pacific/4:30 p.m. Central European time

Live webcast access: Go towww.celltherapeutics.com. The audio presentation
with slides will be available approximately two hours after the end of the

About Pacritinib

Pacritinib is an oral, once-a-day, tyrosine kinase inhibitor (TKI) with dual
activity against JAK2 and FLT3. The JAK family of enzymes are a central
component in signal transduction pathways, which are critical to normal blood
cell growth and development as well as inflammatory cytokine expression and
immune responses. Mutations in these kinases have been shown to be directly
related to the development of a variety of blood related cancers including
myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an
advantage over other JAK inhibitors through effective treatment of symptoms
while having less treatment-emergent thrombocytopenia and anemia than has been
seen in currently approved and in-development JAK inhibitors. Pacritinib has
demonstrated encouraging results in Phase 1 and 2 studies for patients with
myelofibrosis. Pacritinib has orphan drug designation in the U.S. andEurope.

About Cell Therapeutics, Inc.

Cell Therapeutics (Nasdaq and MTA: CTIC) is a biopharmaceutical company
committed to the development and commercialization of an integrated portfolio
of oncology products aimed at making cancer more treatable. CTI is
headquartered in Seattle, WA. For additional information and to sign up for
email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number
of risks and uncertainties the outcome of which could materially and/or
adversely affect actual future results and the market price of CTI's
securities. Specifically, the risks and uncertainties that could affect the
development of pacritinib include risks associated with preclinical and
clinical developments in the biopharmaceutical industry in general, and with
pacritinib in particular, including, without limitation, the potential failure
of pacritinib to prove safe and effective for the treatment of patients with
myelofibrosis, either alone or in combination regimens, as determined by the
U.S. Food and Drug Administration and/or the European Medicines Agency; that
the PERSIST-1 clinical trial may not occur as planned; that pacritinib may not
offer an advantage over other JAK inhibitors; that CTI may not be able to
successfully implement its plans, strategies and objectives related to the
development of pacritinib; CTI's ability to continue to raise capital as
needed to fund its operations, competitive factors, technological
developments, costs of developing, producing and selling CTI's product
candidates; and the risk factors listed or described from time to time in
CTI's filings with the Securities and Exchange Commission including, without
limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as
may be required by law, CTI does not intend to update or alter its
forward-looking statements whether as a result of new information, future
events, or otherwise.


Monique Greer
+1 206.272.4343

Ed Bell
+1 206.282.7100

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
Press spacebar to pause and continue. Press esc to stop.